S&P 500 Gains & Losses Today: Johnson & Johnson Stock Jumps; Universal Health Services Shares Slide
The S&P 500 ticked 0.3% higher on Wednesday, July 16, 2025, as President Trump addressed concerns that a dismissal of Fed Chair Jerome Powell could be imminent.
Johnson & Johnson shares pushed higher after the health care giant reported better-than-expected quarterly results.
Shares of Universal Health Services fell after BofA analysts downgraded the stock, citing headwinds related to recent health care legislation.Major U.S. equities indexes ticked higher Wednesday as President Donald Trump refuted reports that he is planning the immediate dismissal of Federal Reserve Chair Jerome Powell and questions about his legal ability to do so.
The S&P 500 added 0.3% in the midweek trading session. The Nasdaq also gained 0.3%, notching a record closing high for a third straight day. The Dow was up 0.5%. Read Investopedia's full coverage of today's trading here.
Shares of Global Payments (GPN) surged 6.5%, the most of any S&P 500 stock, following reports that activist investor Elliott Management has accumulated a significant stake in the financial technology firm. Global Payments shares took a hit in April when the company agreed to acquire payment processor Worldpay in a cash-and-stock deal worth more than $24 billion.
Johnson & Johnson (JNJ) shares jumped 6.2%. The medical device and drug maker topped sales and profit forecasts with its second-quarter results and boosted its full-year guidance. CEO Joaquin Duato said Johnson & Johnson is positioned for growth in the second half of 2025, highlighting approvals and expected submissions across various medical areas.
U.S.-based asset manager Apollo Global Management (APO) is reportedly in discussions about a potential investment in Spanish soccer club Atletico Madrid. Although Apollo's initial meetings with the club were focused on financing Atletico's 800-million-euro development project surrounding Madrid's Metropolitano Stadium, the firm is now reportedly interested in acquiring a stake in the team's majority owner. Apollo Global Management shares gained 4.8%.
Shares of engineering and design software firm Ansys (ANSS) fell 4.7%, posting the benchmark index's weakest daily performance. Wednesday's downturn gave back some of the gains posted by the stock earlier in the week after regulators in China granted conditional approval for the $35 billion buyout of Ansys by fellow software provider Synopsys (SNPS). S&P Dow Jones Indices said Tuesday that Ansys stock will exit the S&P 500 later this week following the closure of the deal, to be replaced by digital advertising firm The Trade Desk (TDD).
Bank of America analysts downgraded Universal Health Services (UHS) stock to "underperform" from "neutral" and lowered their price target. Shares of the hospital operator fell 3.8%. Analysts cited concerns about health care legislation, including cuts to Medicaid and Affordable Care Act, or ACA, exchanges, which they believe could pressure patient volumes and increase hospitals' exposure to bad debt. BofA indicated that UHS is highly vulnerable to changes in state directed payments.
Shares of memory chipmaker Micron Technology (MU) sank 3.1% after Goldman Sachs initiated coverage of the stock with a "neutral" rating. Although Goldman analysts said Micron could benefit from an eventual rebound in the NAND flash memory market heading into 2026, they maintain a cautious stance on the overall semiconductor space, revenues for which it expects will remain relatively stable through next year.
Read the original article on Investopedia
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Open Sauce's Eye-catching Creations? Meet Elegoo's AI Robots, Glowing Cosplay Wings, and More, All 3D Printed
SAN FRANCESCO, July 18, 2025 /PRNewswire/ -- Elegoo, a rapidly developing brand in global smart manufacturing, joins Open Sauce today, one of the world's biggest gatherings of makers, creators, and tech innovators - at Booth A15 and A16, the San Mateo County Event Center. During the 3-day event from July 18 to July 20 in San Francisco, Elegoo is unveiling a lineup of 3D printed creations built around STEM ideas and co-created with creators worldwide. "We're here at Open Sauce because it celebrates the maker spirit we believe in," said Coco Lee, Brand Director at Elegoo. "This isn't just a place to show off tech - it's where people come to make it their own. We're here to co-create, spark ideas, explore collaborations, and most of all, deliver the fun and wonder of 3D printing." Elegoo for the first time presents some of the coolest creations including: Open-source AI robot fleet of nine: 3D printed by Elegoo's passionate engineers, these robots run on the ESP32-S3 chip and draw inspiration from the Otto robot and the open-source XiaoZhi AI project. Elegoo expanded on this idea by 3D printing custom shells, while redesigning the control board and rewriting the firmware to create their own version. The robots can listen, speak, display expressions, take photos, perform movements as instructed, and interpret user intent through AI with the help of sensors. This open-source foundation blends 3D printing, AI, and robotics into one accessible platform, inspiring developers around the world. Animatronic Wings: Co-created with Willow Creative in just four weeks, this project turns heads and shows the power of 3D printing. Most parts, including feathers, hinges, connectors, and backpack frame, are 3D printed with the OrangeStorm Giga and Centauri Carbon. Each feather is made of transparent PETG to work with addressable 3mm LED strips, allowing for dynamic light effects. Tipsy: Totally Intelligent Pouring System (Tipsy) is an AI-powered drink pouring machine created by Concept Bytes, with support from Elegoo for 3D printers and materials. Its entire outer casing is 3D printed. The machine connects up to 12 drink sources via tubing and uses small pumps to precisely dispense single or double shots. A digital control panel displays ChatGPT-generated drink images, adding a fun and customizable touch. Tipsy is fully open-source and was made using the Centauri Carbon. GlowGear: A futuristic cosplay sword created in collaboration with Little Jem. It features smoke effects and sound, and was printed on the Centauri Carbon with 120 hours of print time. Besides exciting projects, visitors can experience Elegoo's latest 3D printers, including the Centauri Carbon and Jupiter 2, and enjoy interactive games and giveaways at the booth. For more information, please follow Elegoo's social media platforms, including Facebook, Instagram, X, YouTube, TikTok, Discord, and Reddit. Event Details: Date: July 18-20, 2025Location: San Mateo County Event Center, 1346 Saratoga Dr, San Mateo, CA, USBooth: A15, 16 About Elegoo Founded in 2015, Elegoo is a rapidly developing brand in the global smart manufacturing industry, specializing in R&D, manufacturing, and sales of consumer-grade 3D printers, laser engravers, STEM kits, and other smart technology products. Located in Shenzhen, the Silicon Valley of China, the company has sold millions of products across more than 100 countries and regions. In 2024, the company's total sales revenue surpassed 220 million USD, with more than 1000 employees and nearly 30,000 square meters of office and manufacturing area. With a focus on programming and 3D printing technology, Elegoo provides unique and smart creation spaces for diverse consumers to enhance personalized experiences. View original content to download multimedia: SOURCE ELEGOO
Yahoo
27 minutes ago
- Yahoo
Owning 67% in ViTrox Corporation Berhad (KLSE:VITROX) means that insiders are heavily invested in the company's future
Key Insights Significant insider control over ViTrox Corporation Berhad implies vested interests in company growth 55% of the business is held by the top 3 shareholders Institutional ownership in ViTrox Corporation Berhad is 18% Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Every investor in ViTrox Corporation Berhad (KLSE:VITROX) should be aware of the most powerful shareholder groups. With 67% stake, individual insiders possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company. So, insiders of ViTrox Corporation Berhad have a lot at stake and every decision they make on the company's future is important to them from a financial point of view. Let's take a closer look to see what the different types of shareholders can tell us about ViTrox Corporation Berhad. Check out our latest analysis for ViTrox Corporation Berhad What Does The Institutional Ownership Tell Us About ViTrox Corporation Berhad? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that ViTrox Corporation Berhad does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at ViTrox Corporation Berhad's earnings history below. Of course, the future is what really matters. Hedge funds don't have many shares in ViTrox Corporation Berhad. Looking at our data, we can see that the largest shareholder is the CEO Jenn Chu with 27% of shares outstanding. Kok Siaw is the second largest shareholder owning 18% of common stock, and Shih Yeoh holds about 10.0% of the company stock. Interestingly, the second and third-largest shareholders also happen to be the Senior Key Executive and Member of the Board of Directors, respectively. This once again signifies considerable insider ownership amongst the company's top shareholders. After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of ViTrox Corporation Berhad The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. It seems that insiders own more than half the ViTrox Corporation Berhad stock. This gives them a lot of power. Insiders own RM4.6b worth of shares in the RM6.8b company. That's extraordinary! It is good to see this level of investment. You can check here to see if those insiders have been selling any of their shares. General Public Ownership The general public-- including retail investors -- own 15% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. Next Steps: I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. The company has dealt with some hurdles in the past, but it has secured several key new drug approvals in recent years. One of the most notable is Reblozyl, a treatment for anemia in individuals with beta-thalassemia, a rare blood disorder. In the first quarter, Reblozyl generated $478 million in sales, marking a 35% increase compared to the same period last year. Bristol-Myers Squibb Company (NYSE:BMY)'s revenue for the year came in at $11.2 billion, which, though, fell by 5.6% from the same period last year, beat analysts' estimates by $494.6 million. The company's cash position also remained strong, with cash and cash equivalents of $10.9 billion, up from $10.34 billion at the end of December 2024. Bristol-Myers Squibb Company (NYSE:BMY) has raised its full-year revenue forecast from around $45.5 billion to a new range of about $45.8 billion to $46.8 billion. This upward revision reflects strong results from its Growth Portfolio, stronger-than-anticipated Legacy Portfolio sales in the first quarter of 2025, and a positive foreign exchange impact of roughly $500 million. Bristol-Myers Squibb Company (NYSE:BMY) offers a quarterly dividend of $0.62 per share and has a dividend yield of 5.18%, as of July 17. The company has been rewarding its shareholders with growing dividends for the past 16 years. While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
